Cullinan Oncology LLC - Asset Resilience Ratio
Cullinan Oncology LLC (CGEM) has an Asset Resilience Ratio of 68.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Cullinan Oncology LLC's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Cullinan Oncology LLC to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cullinan Oncology LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cullinan Oncology LLC (CGEM) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $276.80 Million | 68.69% |
| Total Liquid Assets | $276.80 Million | 68.69% |
Asset Resilience Insights
- Very High Liquidity: Cullinan Oncology LLC maintains exceptional liquid asset reserves at 68.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cullinan Oncology LLC Industry Peers by Asset Resilience Ratio
Compare Cullinan Oncology LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Cullinan Oncology LLC (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Cullinan Oncology LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.58% | $289.56 Million | $448.37 Million | +13.77pp |
| 2024-12-31 | 50.81% | $315.97 Million | $621.82 Million | -25.32pp |
| 2023-12-31 | 76.14% | $368.63 Million | $484.18 Million | +20.69pp |
| 2022-12-31 | 55.45% | $311.14 Million | $561.12 Million | +2.68pp |
| 2021-12-31 | 52.77% | $230.69 Million | $437.19 Million | +33.20pp |
| 2020-12-31 | 19.57% | $42.01 Million | $214.71 Million | -15.65pp |
| 2019-12-31 | 35.22% | $35.38 Million | $100.46 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $34.64 Million | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more